Alkem Laboratories Limited

BSE: 539523 NSE: ALKEM
Alkem Laboratories Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L00305MH1973PLC174201 Incorporated 08 August 1973 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: ALKEM · BSE: 539523 Public Limited Company pharma Fortune India 500 · #202 Nifty 500
Data last updated
Market Cap
₹60,141 Cr
ALKEM · NSE
Share Price
₹5,078.00
+0.95% today
Revenue
₹14,712 Cr
FY 2025-26 · +13.5% YoY
EBITDA
₹2,816 Cr
Margin 19.1%
Net Profit
₹2,440 Cr
FY 2025-26 · +13.0% YoY
P/E (TTM)
26.0x
P/B 4.3x
ROE
18.2%
ROCE 19.7%
Debt / Equity
0.13
Interest cover 6.6x

About Alkem Laboratories Limited

Data last updated:

Alkem Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 August 1973 and has been in existence for over 53 years.

Alkem Laboratories is ranked #202 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L00305MH1973PLC174201. Its GSTIN is 27AABCA9521E1ZX (Maharashtra). The company holds 37 GST registrations, of which 29 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 539523 and NSE: ALKEM.

The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹23.91 Cr. It was formerly known as Alkem Laboratories Private Limited. It is led by directors including Sandeep Singh (Managing Director) and Srinivas Balmiki Prasad Singh (Whole-Time Director).

Its last annual general meeting (AGM) was held on 27 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹14,712 Cr, a growth of 13.5% compared to the previous year. For the same year it recorded a net profit of ₹2,440.07 Cr (net margin 16.6%) and EBITDA of ₹2,816.09 Cr (EBITDA margin 19.1%). The net worth stands at ₹13,820 Cr (up 15.3% YoY). Total assets are valued at ₹17,253 Cr (up 18.7% YoY).

The company has about 18,498 employees on its provident fund (EPFO) records. Its group structure includes 5 subsidiaries.

The company is associated with 4 brands: Connect2Clinic, Alkem Laboratories Ltd, Enzene Biosciences and Alkem Laboratories. As per MCA filings, the company has open charges of ₹1,085.77 Cr and satisfied charges of ₹4,919.56 Cr on record. Court records list 702 cases involving the company, including 507 filed by the company and 196 filed against it; 235 cases are pending. The company has 28 deals on record (18 market trades, 9 secondary share transfers, 1 ipo); the latest was in June 2026. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Zydus Lifesciences Limited with revenue of ₹23,511 Cr. The company has 35 MSME Form 1 returns on record between 2016 and 2024, listing 14,923 overdue payments to 942 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alkemlabs.com.

Company details

CIN L00305MH1973PLC174201
Registration Number 174201
Incorporation Date 08 August 1973
ROC Mumbai
Listing Status Listed - Listed on NSE (ALKEM); Listed on BSE (539523)
Company Status Active
Date of Last AGM 27 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Alkem Laboratories has one previous CIN (Corporate Identification Number): U00305MH1973PLC174201. The current CIN is L00305MH1973PLC174201, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L00305MH1973PLC174201Current
U00305MH1973PLC174201Previous
Key People
Sandeep Singh Managing Director Srinivas Balmiki Prasad Singh Whole-Time Director Basudeo Narayan Singh Whole-Time Director

Recognitions & Rankings of Alkem Laboratories

Fortune India 500 2025 edition
Rank#202
Total income
₹13,648 Cr
Profit
₹2,165 Cr
Last year #191
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#103
Valuation
₹65,610 Cr
2023 #109 2022 #116 2021 #92
Stock market indices
Nifty 500 BSE 500

Contact details

Alkem Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is alkemlabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    alkemlabs.com
  • Social Media
  • Registered Address
    Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Alkem Laboratories Limited, buy the company report.

Comprehensive company report
Alkem Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Alkem Laboratories operates multiple associated brands including Connect2Clinic, Alkem Laboratories Ltd, and Enzene Biosciences. Each brand links to its own profile.

BrandDescriptionWebsite
Connect2Clinic
Provides comprehensive teleconsultation solutions for patients and healthcare professionals.connect2clinic.com
Enzene Biosciences
Company specializing in development of Biosimilarsenzene.com
Alkem Laboratories
Pharmaceutical generics, formulations, and nutraceuticals are manufactured for therapeutic segments.alkemlabs.com
Alkem Laboratories Ltd
Production of FOS and related dietary fibers for food and health applications in India.foshealth.in

Business activity

The main business activities of Alkem Laboratories are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Alkem Laboratories Limited, buy the company report.

Financials of Alkem Laboratories Limited

FY 2025-26 filings available

Alkem Laboratories Limited reported revenue of ₹14,712 Cr (up 13.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹14,712 Cr
+13.5% YoY
EBITDA
₹2,816 Cr
+12.1% YoY
Profit After Tax
₹2,440 Cr
+13.0% YoY
Net Worth
₹13,820 Cr
+15.3% YoY
Total Assets
₹17,253 Cr
+18.7% YoY
Total Debt
₹2,047 Cr
+48.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14,71212,96512,66811,59910,6348,8658,344
Revenue growth+13.5%+2.3%+9.2%+9.1%+20.0%+6.2%-
EBITDA2,8162,5122,1241,5062,0381,9421,473
EBITDA margin+19.1%+19.4%+16.8%+13.0%+19.2%+21.9%+17.7%
Profit before tax2,8712,5272,0231,3051,8441,8421,260
Net profit2,4402,1601,8941,0731,6561,5551,126
Net profit margin+16.6%+16.7%+15.0%+9.3%+15.6%+17.5%+13.5%
EPS (₹)192.54181.14150.2182.32137.65132.5894.28
Balance sheet
Total assets17,25314,53312,77011,37611,8569,5888,243
Net worth13,82011,98510,3129,0458,6387,3776,161
Total debt2,0471,3811,4181,3972,6681,7071,616
Cash & bank1,7331,5631,5792,6172,5791,9901,092
Net working capital7,8686,7517,4576,0326,0814,8193,633
Cash flow
Cash from operations1,9631,9131,9481,6821,1111,265585
Cash from investing(1,682)(1,288)(1,011)120(1,433)(995)(737)
Cash from financing(503)(811)(1,145)(1,761)380(272)79.15
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue3,7403,6033,7374,0013,3713,1443,3743,415
Revenue growth (YoY)+11.0%+14.6%+10.7%+17.2%+11.2%---
Other income15320014310414914692.99134
EBITDA766382775921739391759753
EBITDA margin+20.5%+10.6%+20.7%+23.0%+21.9%+12.4%+22.5%+22.0%
Depreciation10010695.0193.6187.6811285.2878.91
Interest46.6253.8842.1035.0229.7828.4236.0328.14
Profit before tax772423781896771396731780
Tax25017112811610373.3390.2878.30
Net profit521252654780668323641702
EPS (₹)43.4919.7753.1963.9955.5625.5752.3457.60
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,6908,8317,9729,0558,8307,2206,677
Revenue growth+9.7%+10.8%-12.0%+2.6%+22.3%+8.1%-
EBITDA2,2672,1561,6071,3771,8101,9361,468
EBITDA margin+23.4%+24.4%+20.2%+15.2%+20.5%+26.8%+22.0%
Profit before tax2,6202,4951,7811,3271,7531,8841,338
Net profit2,4022,2751,8051,1451,5391,6691,261
Net profit margin+24.8%+25.8%+22.6%+12.6%+17.4%+23.1%+18.9%
EPS (₹)190.89190.79146.1494.90128.92140.95105.76
Balance sheet
Total assets15,07113,44711,89910,82311,3019,2077,729
Net worth13,99912,32210,5559,3508,7447,6266,280
Total debt6114391,0051,1822,2941,3841,209
Cash & bank1,2891,0561,0662,1642,2971,673766
Net working capital5,0994,5515,7584,5514,8583,9032,691
Cash flow
Cash from operations1,9692,1891,6871,4371,2991,324682
Cash from investing(1,461)(1,007)(866)197(1,669)(1,121)(995)
Cash from financing(673)(1,037)(959)(1,711)437(209)173
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,6682,2582,4912,5422,3722,0452,2872,355
Revenue growth (YoY)+12.5%+10.4%+8.9%+8.0%+11.5%---
Other income137206132164165163216176
Total expenses1,9312,0341,8401,7711,7521,7481,6291,714
EBITDA737225651771620297658640
EBITDA margin+27.6%+10.0%+26.1%+30.3%+26.2%+14.5%+28.8%+27.2%
Depreciation57.2278.1760.9158.5958.8991.6467.6161.30
Interest17.5216.2415.5112.7512.7916.9121.0017.18
Profit before tax798336706864714351785738
Tax22811984.0177.0557.4173.9562.1740.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue3,7403,6033,7374,0013,3713,1443,3743,415
Revenue growth (YoY)+11.0%+14.6%+10.7%+17.2%+11.2%---
Other income15320014310414914692.99134
EBITDA766382775921739391759753
EBITDA margin+20.5%+10.6%+20.7%+23.0%+21.9%+12.4%+22.5%+22.0%
Depreciation10010695.0193.6187.6811285.2878.91
Interest46.6253.8842.1035.0229.7828.4236.0328.14
Profit before tax772423781896771396731780
Tax25017112811610373.3390.2878.30
Net profit521252654780668323641702
EPS (₹)43.4919.7753.1963.9955.5625.5752.3457.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14,71212,96512,66811,59910,6348,8658,344
Revenue growth+13.5%+2.3%+9.2%+9.1%+20.0%+6.2%-
Other income598494311216163233104
Total expenses11,89610,45210,54410,0938,5966,9236,871
Employee cost2,8372,4542,2012,1311,9631,6211,505
EBITDA2,8162,5122,1241,5062,0381,9421,473
EBITDA margin+19.1%+19.4%+16.8%+13.0%+19.2%+21.9%+17.7%
Depreciation382357299310304275253
Interest16112211210752.3758.9265.06
Profit before tax2,8712,5272,0231,3051,8441,8421,260
Tax518311212298164224110
Net profit2,4402,1601,8941,0731,6561,5551,126
Net profit margin+16.6%+16.7%+15.0%+9.3%+15.6%+17.5%+13.5%
EPS (₹)192.54181.14150.2182.32137.65132.5894.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.9123.9123.9123.9123.9123.9123.91
Reserves & surplus13,79611,96110,2889,0218,6147,3536,137
Shareholders' funds (net worth)13,82011,98510,3129,0458,6387,3776,161
Minority interest529449402390209181148
Secured loans7244414293011,335693634
Unsecured loans1,3239409901,0961,3331,014981
Total debt2,0471,3811,4181,3972,6681,7071,616
Total liabilities17,25314,53312,77011,37611,8569,5888,243
Assets
Gross block6,0704,7204,5444,0504,1863,7693,607
Net block3,8712,8522,8732,6832,9022,7932,908
Capital work in progress282548159323339393363
Investments1,8691,846484622371333261
Inventories3,3332,9222,6612,6083,0062,3121,819
Sundry debtors2,9792,4662,2532,1321,8851,6071,649
Cash & bank balances1,7331,5631,5792,6172,5791,9901,092
Loans & advances3,4282,9573,7691,056826840775
Total current assets11,4739,90910,2638,4128,2946,7505,336
Total current liabilities3,6053,1582,8052,3812,2131,9311,703
Net working capital7,8686,7517,4576,0326,0814,8193,633
Total assets17,25314,53312,77011,37611,8569,5888,243
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(120)66.31274232174176249
Net cash from operating activities1,9631,9131,9481,6821,1111,265585
Net cash from investing activities(1,682)(1,288)(1,011)120(1,433)(995)(737)
Net cash from financing activities(503)(811)(1,145)(1,761)380(272)79.15
Net change in cash(222)(186)(207)41.6257.96(1.72)(73.11)
Closing cash1,7331,5631,5792,6172,5791,9901,092
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.5%+2.3%+9.2%+9.1%+20.0%+6.2%-
EBITDA growth+12.1%+18.3%+41.0%-26.1%+4.9%+31.8%-
PBT growth+13.6%+24.9%+55.1%-29.3%+0.1%+46.2%+32.0%
Net income growth+13.0%+14.0%+76.5%-35.2%+6.5%+38.0%-
Revenue CAGR (3Y)+8.3%+6.8%+12.6%+11.6%+13.1%+11.5%+13.6%
EBITDA CAGR (3Y)+23.2%+7.2%+3.0%+0.7%+22.3%+24.4%+13.8%
Profitability & leverage
Net income margin+16.0%+17.1%+14.3%+8.7%+15.8%+18.3%+13.8%
Return on capital employed+19.7%+20.0%+18.3%+12.5%+18.0%+21.7%+18.1%
Return on net worth+18.2%+19.9%+18.7%+11.4%+21.0%+23.9%+19.8%
Debt / equity0.130.130.150.230.270.250.22
Long-term debt / equity0.060.040.020.010.010.010.03
Interest cover6.615.656.168.983.023.535.33
Efficiency & per share
Fixed asset turnover2.732.802.952.822.672.402.52
Inventory turnover4.704.644.814.134.004.295.03
Debtors turnover5.405.495.785.786.095.445.76
EPS (₹)192.54181.14150.2182.32137.65132.5894.28
Dividend per share (₹)53.0045.0040.0050.0034.0030.0025.00
Book value per share (₹)1,156.011,002.50862.57756.61722.53617.04515.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,6682,2582,4912,5422,3722,0452,2872,355
Revenue growth (YoY)+12.5%+10.4%+8.9%+8.0%+11.5%---
Other income137206132164165163216176
Total expenses1,9312,0341,8401,7711,7521,7481,6291,714
EBITDA737225651771620297658640
EBITDA margin+27.6%+10.0%+26.1%+30.3%+26.2%+14.5%+28.8%+27.2%
Depreciation57.2278.1760.9158.5958.8991.6467.6161.30
Interest17.5216.2415.5112.7512.7916.9121.0017.18
Profit before tax798336706864714351785738
Tax22811984.0177.0557.4173.9562.1740.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,6908,8317,9729,0558,8307,2206,677
Revenue growth+9.7%+10.8%-12.0%+2.6%+22.3%+8.1%-
Other income66669849326620019095.98
Total expenses7,4236,6756,3657,6787,0195,2845,209
Employee cost1,8831,6317381,5161,4341,1591,067
EBITDA2,2672,1561,6071,3771,8101,9361,468
EBITDA margin+23.4%+24.4%+20.2%+15.2%+20.5%+26.8%+22.0%
Depreciation257284239230219199187
Interest57.2976.1180.0786.4037.9042.9338.71
Profit before tax2,6202,4951,7811,3271,7531,8841,338
Tax33821433.6219321219973.66
Net profit2,4022,2751,8051,1451,5391,6691,261
Net profit margin+24.8%+25.8%+22.6%+12.6%+17.4%+23.1%+18.9%
EPS (₹)190.89190.79146.1494.90128.92140.95105.76
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.9123.9123.9123.9123.9123.9123.91
Reserves & surplus13,97512,29810,5319,3268,7207,6026,257
Shareholders' funds (net worth)13,99912,32210,5559,3508,7447,6266,280
Secured loans21862.881721191,010328239
Unsecured loans3933768331,0621,2841,056971
Total debt6114391,0051,1822,2941,3841,209
Total liabilities15,07113,44711,89910,82311,3019,2077,729
Assets
Gross block3,2173,0833,1442,9322,8272,4822,352
Net block1,5501,5911,7821,8251,8821,7581,837
Capital work in progress12376.5090.78229232323314
Investments5,5524,4072,8293,0062,5292,1521,956
Inventories1,6321,5231,8501,7251,9761,5131,093
Sundry debtors1,5671,5601,7541,7681,7681,5571,555
Cash & bank balances1,2891,0561,0662,1642,2971,673766
Loans & advances2,8002,5603,227803684726654
Total current assets7,2896,6997,8966,4606,7255,4694,068
Total current liabilities2,1902,1482,1391,9081,8681,5661,377
Net working capital5,0994,5515,7584,5514,8583,9032,691
Total assets15,07113,44711,89910,82311,3019,2077,729
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.04(133)5.0181.8215.2220.69161
Net cash from operating activities1,9692,1891,6871,4371,2991,324682
Net cash from investing activities(1,461)(1,007)(866)197(1,669)(1,121)(995)
Net cash from financing activities(673)(1,037)(959)(1,711)437(209)173
Net change in cash(165)145(138)(76.81)66.60(5.47)(141)
Closing cash1,2891,0561,0662,1642,2971,673766
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.7%+10.8%-12.0%+2.6%+22.3%+8.1%-
EBITDA growth+5.1%+34.2%+16.7%-23.9%-6.5%+31.9%-
PBT growth+5.0%+40.1%+34.2%-24.3%-7.0%+40.8%+41.8%
Net income growth+5.6%+26.1%+57.7%-25.6%-7.7%+32.3%-
Revenue CAGR (3Y)+2.3%0.0%+3.4%+10.7%+15.6%+11.0%+13.7%
EBITDA CAGR (3Y)+18.1%+6.0%-6.0%-2.1%+20.1%+25.8%+18.7%
Profitability & leverage
Net income margin+23.6%+25.8%+21.9%+12.5%+17.5%+23.3%+18.9%
Return on capital employed+18.8%+20.3%+16.4%+12.8%+17.5%+22.8%+19.9%
Return on net worth+17.3%+19.9%+17.6%+12.5%+18.8%+24.2%+21.5%
Debt / equity0.040.060.110.190.220.190.15
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover2.854.065.857.532.382.473.02
Efficiency & per share
Fixed asset turnover3.082.842.623.143.332.993.09
Inventory turnover6.145.244.464.895.065.546.41
Debtors turnover6.205.334.535.125.314.645.30
EPS (₹)190.89190.79146.1494.90128.92140.95105.76
Dividend per share (₹)53.0045.0040.0050.0034.0030.0025.00
Book value per share (₹)1,170.951,030.68882.86782.09731.38637.87525.34

To see the full year-wise statements and ratios of Alkem Laboratories Limited, buy the company report.

Board of directors of Alkem Laboratories Limited

Alkem Laboratories has 12 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sujjain Suresh Talwar
Also directs: Elantas Beck India Limited, Carborundum Universal Limited, Integrated Mumbai Business Park (India) Private Limited and 2 more
Director05 Aug 20224 Years 2 MonthsCurrent
Srinivas Balmiki Prasad Singh
Also directs: Alkem Foundation, Alixer Nexgen Therapeutics Limited
Whole-Time Director14 Sep 20224 Years 1 MonthsCurrent
Sandeep Singh
Also directs: Alkem Wellness Limited, Alkem Medtech Private Limited, Connect 2 Clinic Private Limited and 5 more
Managing Director09 Aug 201313 Years 2 MonthsCurrent
Basudeo Narayan Singh
Also directs: Alkem Wellness Limited, Amplira Ventures LLP, Alkem Medtech Private Limited and 1 more
Whole-Time Director08 Aug 197353 Years 2 MonthsCurrent
Mritunjay Kumar Singh
Also directs: Indchemie Health Specialities Private Limited, Connect 2 Clinic Private Limited, Alkem Foundation
Whole-Time Director11 Feb 200818 Years 8 MonthsCurrent
Laxmana Ranjal Shenoy
Also directs: Indchemie Health Specialities Private Limited
Director13 Jul 20251 Years 3 MonthsCurrent
Showing 6 of 12 current directors. View all directors

Peer comparison

Alkem Laboratories Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Zydus Lifesciences Limited₹23,511 Cr (FY 2025)19.0%Ahmedabad, Gujarat, India
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Biocon Limited₹16,470 Cr (FY 2025)5.0%Bengaluru, Karnataka, India
Alkem Laboratories Limitedthis company₹14,712 Cr (FY 2026)₹2,440.07 Cr16.6%13.5%18,498Mumbai, Maharashtra, India
Glenmark Pharmaceuticals Limited₹13,435 Cr (FY 2025)6.0%Mumbai, Maharashtra, India
Torrent Pharmaceuticals Ltd₹11,539 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Serum Institute of India Private Limited₹10,854 Cr (FY 2025)-2.0%Pune, Maharashtra, India
Macleods Pharmaceuticals Ltd₹9,671.68 Cr (FY 2025)5.0%Mumbai, Maharashtra, India

To see the full peer comparison of Alkem Laboratories Limited, buy the company report.

Auditor

Alkem Laboratories Limited is audited by BSR & Co. LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
BSR & Co. LLPFY 2024101248W/W100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 49.70%, foreign institutional investors hold 10.40%, domestic institutional investors hold 22.70% and retail and other public shareholders hold 17.20%.

Promoters: 49.70%DII (Domestic Institutional): 22.70%FII (Foreign Institutional): 10.40%Retail & Others: 17.20%
Sep 2026
QUARTER
49.70% Promoters
22.70% DII (Domestic Institutional)
10.40% FII (Foreign Institutional)
17.20% Retail & Others
Promoter holding - history
Now 49.70% · Sep 2026High 51.20% · Dec 2025Low 49.70% · Sep 2026
48%49.3%50.5%51.8%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.20%Mar 2026: 51.20%Jun 2026: 51.20%Sep 2026: 49.70%51.20%49.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters49.70%51.20%51.20%51.20%
Public50.30%48.80%48.80%48.80%

Charges & borrowings

Open charges
₹1,085.77 Cr
Satisfied charges
₹4,919.56 Cr
Breakdown by lending institutions
Citi Bank N.A.₹341.96 Cr
Others₹288.00 Cr
Hdfc Bank Limited₹270.32 Cr
State Bank of India₹100.20 Cr
Bank of India₹85.00 Cr
Others₹0.30 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
15 Jul 2024100957959Others₹100 CrOpen
26 Feb 2024100879823Others₹108 CrOpen
07 Oct 2023100794596Bank of India₹85 CrOpen
24 Aug 2023100777766Others₹80 CrOpen
27 Mar 2023100705456Hdfc Bank Limited₹270.32 CrOpen

To see the full charge records of Alkem Laboratories Limited, buy the company report.

Total charge records: 46 View all charges

Deals & funding

Alkem Laboratories Limited has 28 deals on record (18 market trades, 9 secondary share transfers, 1 ipo); the latest was in June 2026.

Total deals
28
Market trades
18
Secondary share transfers
9
IPO
1

Deals on record (5 of 28)

WhenDealAmountParties
Jun 2026Market trade₹643.87 CrBuyer: Icici Prudential Mutual Fund
Seller: an individual
Jun 2026Market trade₹929.87 CrBuyer: Icici Prudential Mutual Fund, Hdfc Mutual Fund, Dsp Mutual Fund
Seller: Samprada&Nanhamati Singh Family Trust, an individual
Jun 2025Market trade₹365 CrSeller: Samprada&Nanhamati Singh Family Trust
Aug 2024Market trade₹487.23 CrBuyer: Icici Prudential Life Insurance Company Limited , Morgan Stanley Asia Singapore Pte-Odi, Tata Mutual Fund
Seller: Samprada&Nanhamati Singh Family Trust
Jun 2024Market trade₹177.77 CrBuyer: Icici Prudential Mutual Fund, Morgan Stanley Investment Management, Aditya Birla Sun Life Mutual Fund
Seller: an individual

To see the full deal history of Alkem Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Alkem Laboratories Limited was last rated by Crisil on 29 Oct 2020.

Rating agencyRated onRating
Crisil29 Oct 2020

To see the full credit ratings and regulatory alerts of Alkem Laboratories Limited, buy the company report.

MSME payment delays

Alkem Laboratories Limited has 35 MSME Form 1 returns on record between 2016 and 2024, listing 14,923 overdue payments to 942 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 942)

SupplierAmount dueDue sinceReported on
Deep Shakti Enterprise
Isa Logistics Private Limited
an individual supplier
Ice Travels & Tour Private Limited
PMP Climate Technologies Private Limited

To see the full MSME payment records of Alkem Laboratories Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Alkem Laboratories has 5 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

5
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Cachet Pharmaceuticals Private LimitedU24230BR1978PTC001328
Indchemie Health Specialities Private LimitedU24230MH1986PTC039692
Enzene Biosciences LimitedU24232PN2006PLC165610
Alkem FoundationU85100MH2010NPL206161
Connect 2 Clinic Private LimitedU93090MH2020PTC339772

To see the full group structure of Alkem Laboratories Limited, buy the company report.

Employees & EPFO

Alkem Laboratories Limited has a workforce of 18,498 employees on its EPFO records as of Nov 19, 2024, across 1 active EPFO establishment.

Employee count
18,498
Active EPFO establishments
1
Employee growth
0.34%

GST

Alkem Laboratories has 37 GST registrations: 29 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
37
Active
29
Cancelled / inactive
8
GSTINStateStatusRegistered on
27AABCA9521E1ZXMaharashtraActive01 Jul 2017
27AABCA9521E2ZWMaharashtraActive14 Jul 2017
27AABCA9521E3ZVMaharashtraActive04 Feb 2021
02AABCA9521E1Z9Himachal PradeshActive01 Jul 2017

To see the full GST registrations and return filing status of Alkem Laboratories Limited, buy the company report.

Recent activity

Alkem Laboratories Limited has 40 board changes on record since 1973: 26 appointments and 14 cessations. The latest: Arun Kumar Purwar ceased to be Director on 13 Jul 2025.

AGM
Alkem Laboratories Limited last Annual general meeting of members was held on 27 Aug 2026 as per latest MCA records.
Filing
Alkem Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Ceased
Arun Kumar Purwar ceased to be Director.
Appointed
Diwakar Gupta was appointed as Director.
Appointed
Laxmana Ranjal Shenoy was appointed as Director.
Appointed
Neela Bhattacherjee was appointed as Director.
Ceased
Sangeeta Kapil Jit Singh ceased to be Director.
Ceased
Sudha Ravi ceased to be Director.
Appointed
Rajeev Kher was appointed as Director.
Charges
A charge with Others amounted to Rs. 100.00 Cr with Charge ID 100957959 was registered on 15 Jul 2024.
Ceased
Dheeraj Sharma ceased to be Director.
Charges
A charge registered on 03 Apr 2023 via Charge ID 100701624 with State Bank Of India was fully satisfied on 13 Jun 2024.

121 earlier events are in the company report.

News

Alkem Laboratories: Company's Audit Committee Greenlights Forensic Audit by Grant Thornton Over Alleged Fund Misuse by Ex-Employee.
21 Oct 2026 · Exchange Update
ALKEM: Rs. 26.69 Crores NSE Block Trade; for ~ 50,611 Shares, at Rs. 5274.00
12 Oct 2026 · Exchange Update
ALKEM: Rs. 26.65 Crores BSE Block Trade; for ~ 50,000 Shares, at Rs. 5330.00
07 Oct 2026 · Exchange Update
ALKEM LAB: CO CFO RESIGNS
24 Sep 2026 · Exchange Update
Alkem Laboratories: Launches Neuceno For Partial-Onset Seizures Treatment In Adults In India, With Once Daily Oral Doses Available.
16 Sep 2026 · Exchange Update

From our blog

Frequently asked questions

Alkem Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 August 1973 (53+ years old) and is registered under CIN L00305MH1973PLC174201. Listed on BSE: 539523 and NSE: ALKEM.

Alkem Laboratories reported revenue of ₹14,712 Cr for FY 2025-26 (up 13.5% YoY) based on consolidated financials.

Alkem Laboratories has 12 current directors:

The latest financial statements of Alkem Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Alkem Laboratories is 27AABCA9521E1ZX, registered in Maharashtra. The company has 37 GST registrations in all, of which 29 are active and 8 are cancelled or inactive. Other active GSTINs include 27AABCA9521E2ZW (Maharashtra), 27AABCA9521E3ZV (Maharashtra), 02AABCA9521E1Z9 (Himachal Pradesh).

The CIN (Corporate Identification Number) of Alkem Laboratories is L00305MH1973PLC174201. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Alkem Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 539523) and NSE (symbol: ALKEM).

Alkem Laboratories has 702 court cases on record: 507 filed by the company and 196 filed against it. 235 are pending. Most are in the high courts.

Alkem Laboratories was incorporated on 08 August 1973, making it 53+ years old. It is registered with the Registrar of Companies, Mumbai.

Alkem Laboratories has 28 deals on record (18 market trades, 9 secondary share transfers, 1 ipo); the latest was in June 2026.

The peers of Alkem Laboratories by revenue are Zydus Lifesciences Limited, Lupin Limited, Intas Pharmaceuticals Limited, Hetero Labs Limited, Biocon Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Arun Kumar Purwar ceased to be Director on 13 Jul 2025. Diwakar Gupta was appointed as Director on 13 Jul 2025. Laxmana Ranjal Shenoy was appointed as Director on 13 Jul 2025. Alkem Laboratories has 40 board changes on record in total.